INM Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of -231.63% compared to InMed Pharmaceuticals's net margin of --. InMed Pharmaceuticals's return on equity of -83.02% beat Edesa Biotech's return on equity of --.

InMed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 17359.28%. On the other hand Edesa Biotech has an analysts' consensus of $19.00 which suggests that it could grow by 829.1%. Given that InMed Pharmaceuticals has higher upside potential than Edesa Biotech, analysts believe InMed Pharmaceuticals is more attractive than Edesa Biotech.

InMed Pharmaceuticals has a beta of 0.477, which suggesting that the stock is 52.253% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.291%.

InMed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

InMed Pharmaceuticals quarterly revenues are $1.1M, which are larger than Edesa Biotech quarterly revenues of --. InMed Pharmaceuticals's net income of -$2.6M is lower than Edesa Biotech's net income of -$1.6M. Notably, InMed Pharmaceuticals's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals is 0.28x versus 20.23x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

ESSA Pharma has a net margin of -231.63% compared to InMed Pharmaceuticals's net margin of --. InMed Pharmaceuticals's return on equity of -83.02% beat ESSA Pharma's return on equity of --.

InMed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 17359.28%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -2.25%. Given that InMed Pharmaceuticals has higher upside potential than ESSA Pharma, analysts believe InMed Pharmaceuticals is more attractive than ESSA Pharma.

InMed Pharmaceuticals has a beta of 0.477, which suggesting that the stock is 52.253% less volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.686, suggesting its more volatile than the S&P 500 by 68.618%.

InMed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

InMed Pharmaceuticals quarterly revenues are $1.1M, which are larger than ESSA Pharma quarterly revenues of --. InMed Pharmaceuticals's net income of -$2.6M is higher than ESSA Pharma's net income of -$8.5M. Notably, InMed Pharmaceuticals's price-to-earnings ratio is -- while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals is 0.28x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of -231.63% compared to InMed Pharmaceuticals's net margin of -1559.32%. InMed Pharmaceuticals's return on equity of -83.02% beat Lexaria Bioscience's return on equity of -118.15%.

InMed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 17359.28%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 548.15%. Given that InMed Pharmaceuticals has higher upside potential than Lexaria Bioscience, analysts believe InMed Pharmaceuticals is more attractive than Lexaria Bioscience.

InMed Pharmaceuticals has a beta of 0.477, which suggesting that the stock is 52.253% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.

InMed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

InMed Pharmaceuticals quarterly revenues are $1.1M, which are larger than Lexaria Bioscience quarterly revenues of $174K. InMed Pharmaceuticals's net income of -$2.6M is higher than Lexaria Bioscience's net income of -$2.7M. Notably, InMed Pharmaceuticals's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals is 0.28x versus 32.73x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of -231.63% compared to InMed Pharmaceuticals's net margin of --. InMed Pharmaceuticals's return on equity of -83.02% beat Xenon Pharmaceuticals's return on equity of --.

InMed Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 17359.28%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.18 which suggests that it could grow by 63.27%. Given that InMed Pharmaceuticals has higher upside potential than Xenon Pharmaceuticals, analysts believe InMed Pharmaceuticals is more attractive than Xenon Pharmaceuticals.

InMed Pharmaceuticals has a beta of 0.477, which suggesting that the stock is 52.253% less volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.174%.

InMed Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InMed Pharmaceuticals pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

InMed Pharmaceuticals quarterly revenues are $1.1M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. InMed Pharmaceuticals's net income of -$2.6M is higher than Xenon Pharmaceuticals's net income of -$65.7M. Notably, InMed Pharmaceuticals's price-to-earnings ratio is -- while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InMed Pharmaceuticals is 0.28x versus 207.11x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.